F.SoucyG.GouletJ.-P.WillemsB.VilleneuveJ.-P.et al (2018)
As with all GLP-1 therapies, there are important safety considerations: Not suitable for individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) May cause nausea, vomiting, diarrhea , especially during dose titration Monitor for signs of pancreatitis , gallbladder issues, or allergic reactions Not indicated for patients with Type 1 diabetes or those with severe gastrointestinal disorders Regular follow-ups, lab monitoring, and dose adjustments are part of the DrWell Methodology to ensure safe, effective outcomes
doi: 10.1038/s41598-019-54118-w 221
Liraglutide exposure increased proportionally in the dose range of 0.6 mg to 3 mg
[8] Elderly ( non -centenarian) test subjects taking you guessed it 2g of l-carnitine twice per day reported similar results in another placebo-controlled, double-blind study
Cells were fixed with 4% paraformaldehyde for 30 min and washed with non-permeabilizing or permeabilizing PBS containing 0.025% Triton-X
